Aiming to help a broader patient population and provide an alternative to opioids, Myoscience Inc., of Fremont, Calif., reported the commercial launch of the Iovera Smart Tip 309.

The U.S. FDA has approved an expanded indication for the Resolute drug-eluting stent (DES) platform – including the Resolute Onyx and Resolute Integrity DES – from Dublin-based Medtronic plc to treat patients with coronary artery disease who have de novo chronic total occlusion (CTO)

Interoperability took center stage at the recent Healthcare Information and Management Systems Society (HIMSS) Conference in Orlando, Fla., with major news coming from the Centers for Medicare and Medicaid Services (CMS) and the Office of the National Coordinator for Health Information Technology (ONC), as well as the release of a report from a group of experts.

Abbott Laboratories and Novo Nordisk A/S, of Bagsvaerd, Denmark, are partnering, with the goal of integrating insulin dose data from the latter's prefilled and durable connected pens into the digital health tools compatible with the Freestyle Libre system. Integrating these two products through this nonexclusive partnership aims to allow health care professionals, caregivers and diabetics to view glucose and insulin data together to help them make more informed treatment decisions.

It has been a busy couple of days for Medtronic plc, with the Dublin-based company reporting results for its third quarter of fiscal year 2019 as revenue beat expectations. Specifically, the company saw third-quarter revenue of almost $7.55 billion, an increase of 2.4 percent as reported or 4.4 percent on an organic basis. Cowen's Joshua Jennings noted that the figure came in ahead of both his group's forecast of $7.48 billion and the consensus estimate of $7.53 billion.